modelB06AA03
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Hyaluronidase | |
| ATC code: | B06AA03 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 1500 | mg |
| volume of distribution: | 4.5 | L |
| clearance: | 20 | L/h |
| other parameters in model implementation | ||
Hyaluronidase is an enzyme that depolymerizes hyaluronic acid, a constituent of the extracellular matrix. It is used to enhance the absorption and dispersion of other injected drugs, improve resorption of radiopaque agents in subcutaneous urography, and in the management of extravasation as well as ophthalmic surgery to facilitate tissue penetration. Hyaluronidase is approved and in clinical use today.
Pharmacokinetics
No published peer-reviewed pharmacokinetic models are available for hyaluronidase in humans. Available data suggest very rapid inactivation following subcutaneous administration, believed to be mainly via tissue and plasma proteases. These estimates are based on indirect and non-quantitative data.
References
Tan, AR, et al., & Jackisch, C (2021). Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. The Lancet. Oncology 22(1) 85–97. DOI:10.1016/S1470-2045(20)30536-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33357420
Li, Z, et al., & Yel, L (2024). Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies. International immunopharmacology 128 111447–None. DOI:10.1016/j.intimp.2023.111447 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38185032
Mateos, MV, et al., & Usmani, SZ (2020). Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. The Lancet. Haematology 7(5) e370–e380. DOI:10.1016/S2352-3026(20)30070-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32213342
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)